Dopaminergic Neurons (SNpc)

Dopaminergic Neurons (Substantia Nigra Pars Compacta)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Dopaminergic Neurons (SNpc)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nigrostriatal</td>
<td>Dorsal striatum (putamen, caudate)</td>
</tr>
<tr>
<td class="label">Mesocortical</td>
<td>Prefrontal cortex</td>
</tr>
<tr>
<td class="label">Mesolimbic</td>
<td>Nucleus accumbens, amygdala</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">L-type Ca2+ channels</td>
<td>Reduce metabolic stress</td>
</tr>
<tr>
<td class="label">α-Synuclein immunotherapy</td>
<td>Clear pathological aggregates</td>
</tr>
<tr>
<td class="label">GLP-1 agonists</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">Anti-inflammatory agents</td>
<td>Reduce neuroinflammation</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">6-OHDA lesion</td>
<td>Catecholaminergic neurotoxin</td>
</tr>
<tr>
<td class="label">MPTP</td>
<td>Complex I inhibitor</td>
</tr>
<tr>
<td class="label">α-Synuclein overexpression</td>

Dopaminergic Neurons (Substantia Nigra Pars Compacta)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Dopaminergic Neurons (SNpc)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000700](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nigrostriatal</td>
<td>Dorsal striatum (putamen, caudate)</td>
</tr>
<tr>
<td class="label">Mesocortical</td>
<td>Prefrontal cortex</td>
</tr>
<tr>
<td class="label">Mesolimbic</td>
<td>Nucleus accumbens, amygdala</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">L-type Ca2+ channels</td>
<td>Reduce metabolic stress</td>
</tr>
<tr>
<td class="label">α-Synuclein immunotherapy</td>
<td>Clear pathological aggregates</td>
</tr>
<tr>
<td class="label">GLP-1 agonists</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">Anti-inflammatory agents</td>
<td>Reduce neuroinflammation</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">6-OHDA lesion</td>
<td>Catecholaminergic neurotoxin</td>
</tr>
<tr>
<td class="label">MPTP</td>
<td>Complex I inhibitor</td>
</tr>
<tr>
<td class="label">α-Synuclein overexpression</td>
<td>Viral or transgenic</td>
</tr>
<tr>
<td class="label">LRRK2 transgenic</td>
<td>Genetic mutation</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Conservation Level</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>High</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Macaque</td>
<td>High</td>
</tr>
<tr>
<td class="label">Zebra finch</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">DaTscan (I123-FP-CIT)</td>
<td>Dopamine transporter</td>
</tr>
<tr>
<td class="label">neuromelanin MRI</td>
<td>SNpc neuromelanin</td>
</tr>
<tr>
<td class="label">18F-DOPA PET</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">MR spectroscopy</td>
<td>N-acetylaspartate</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">TH immunoreactivity</td>
<td>High</td>
</tr>
<tr>
<td class="label">DAT binding</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Neuromelanin</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Low</td>
</tr>
</table>

Overview

Dopaminergic neurons of the substantia nigra pars compacta (SNpc) are midbrain neurons that synthesize and release dopamine, playing essential roles in voluntary movement, reward processing, and motivation. These neurons are the primary population lost in Parkinson's disease (PD), making them central to understanding motor symptoms and developing neuroprotective therapies.

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: dopaminergic neuron (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

Classification & Lineage

• Parent Classification: Catecholaminergic
• Full Lineage: Neuron > Catecholaminergic > Dopaminergic
• Brain Regions: Substantia nigra pars compacta, Ventral tegmental area

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
• [OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Neuroanatomy

The substantia nigra pars compacta (SNpc) is located in the ventral midbrain, dorsal to the cerebral peduncles. Key anatomical features include:

• Location: Ventral midbrain tegmentum, medial to substantia nigra pars reticulata (SNpr)
• Nomenclature: "Substantia nigra" (black substance) derives from neuromelanin pigment accumulation
• Cell count: Approximately 400,000-600,000 dopaminergic neurons in adult human SNpc[@pakkenberg1991]
• Subregional organization: Calbindin-negative neurons in ventral tier show greatest PD vulnerability[@yamada1990]

Projection Pathways

Molecular Biology

Dopamine Synthesis Enzymes

Tyrosine Hydroxylase (TH)

• Rate-limiting enzyme converting tyrosine to L-DOPA
• Requires tetrahydrobiopterin (BH4) as cofactor
• Phosphorylation at Ser31 and Ser40 increases activity[@haycock1990]
• Regulated by feedback inhibition by dopamine

• Converts L-DOPA to dopamine
• Pyridoxal phosphate (vitamin B6) dependent
• Also present in serotonergic neurons (converts 5-HTP to serotonin)

• Transports dopamine into synaptic vesicles
• H+/monoamine antiporter using vesicular proton gradient
• Essential for preventing cytosolic dopamine toxicity[@guillot2009]

Dopamine Transporter (DAT/SLC6A3)

• Reuptake transporter on presynaptic terminals
• Na+/Cl--dependent symporter
• Concentrated in striatal terminals, low in somatodendritic compartments
• Target for cocaine, amphetamine, and dopamine transporter imaging[@nirenberg1997]

Calcium-Binding Proteins

SNpc dopaminergic neurons show relatively low expression of calcium-buffering proteins:

• Calbindin-D28k: Absent in most vulnerable neurons[@yamada1990]
• Calretinin: Variable expression
• Parvalbumin: Generally absent

Electrophysiology

Pacemaking Activity

SNpc dopaminergic neurons exhibit autonomous pacemaking at 1-5 Hz:

• Slow oscillatory potential (SOP): Subthreshold oscillation driving regular spiking
• L-type calcium channels (Cav1.3): Required for pacemaking[@surmeier2010]
• SK potassium channels: Shape afterhyperpolarization
• HCN channels: Contribute to resting membrane properties

Burst Firing

During reward-prediction error signaling:

• Brief high-frequency bursts (15-20 Hz)
• Driven by glutamatergic inputs from pedunculopontine nucleus and subthalamic nucleus
• NMDA receptor-dependent
• Dopamine release scales non-linearly with frequency

Dopamine Release

• Axonal release: At striatal terminals, vesicular, calcium-dependent
• Somatodendritic release: From SNpc soma/dendrites, volume transmission
• D2 autoreceptor feedback: Inhibits further dopamine release and firing

Parkinson's Disease Pathophysiology

Selective Vulnerability

SNpc dopaminergic neurons are disproportionately vulnerable in PD. Factors contributing to this vulnerability include:

1. Calcium-Induced Stress

• L-type Cav1.3 channels create sustained calcium entry during pacemaking
• Low calbindin expression limits buffering capacity
• Mitochondrial calcium overload leads to oxidative stress[@surmeier2010]

• Cytosolic dopamine can auto-oxidize to reactive quinones
• Dopamine metabolism generates hydrogen peroxide via monoamine oxidase (MAO)
• Neuromelanin formation as byproduct may initially be protective but accumulates iron[@zucca2017]

• Alpha-synuclein aggregates form Lewy bodies
• Oligomeric species may disrupt vesicular trafficking
• SNCA gene duplication/triplication causes familial PD[@singleton2003]

• Complex I deficiency consistently observed in PD brain and platelets[@schapira1990]
• PINK1/Parkin pathway disruption impairs mitophagy
• Environmental Complex I inhibitors (MPTP, rotenone) cause parkinsonism

• Microglial activation in SNpc
• Pro-inflammatory cytokines exacerbate neuronal damage
• Peripheral inflammation may accelerate neurodegeneration

Braak Staging

Proposed progression of PD pathology:

• Stage 1-2: Dorsal motor nucleus of vagus, olfactory bulb
• Stage 3-4: SNpc, amygdala (motor symptom onset)
• Stage 4-6: Neocortex (cognitive decline)

Compensatory Mechanisms

Before motor symptoms appear (~50% neuron loss):

• Increased dopamine synthesis per surviving neuron
• Dopamine turnover upregulation
• Postsynaptic receptor supersensitivity
• Contralateral motor cortex compensation

Other Neurodegenerative Diseases

Multiple System Atrophy (MSA)

• SNpc degeneration more severe than typical PD
• Less compensatory dopamine increase
• Olivopontocerebellar involvement distinguishes MSA-C
• Striatonigral degeneration in MSA-P

Dementia with Lewy Bodies (DLB)

• SNpc involvement with cortical Lewy bodies
• Fluctuating cognition, visual hallucinations
• Cognitive symptoms precede or coincide with motor symptoms

Progressive Supranuclear Palsy (PSP)

• SNpc degeneration with 4R tau pathology
• More symmetric onset than PD
• Prominent vertical gaze palsy
• Poor levodopa response

Therapeutic Targets

Dopamine Replacement

Levodopa/Carbidopa

• Gold standard symptomatic therapy
• Carbidopa inhibits peripheral AADC
• Long-term complications: motor fluctuations, dyskinesias

• Pramipexole, ropinirole, rotigotine
• Direct D2/D3 receptor stimulation
• Lower dyskinesia risk, more neuropsychiatric side effects

• Selegiline, rasagiline, safinamide
• Block dopamine metabolism
• Mild symptomatic benefit, potential neuroprotection

Neuroprotective Strategies

Deep Brain Stimulation (DBS)

• Subthalamic nucleus (STN) or globus pallidus interna (GPi) targets
• Reduces motor fluctuations and dyskinesias
• Does not slow disease progression
• Improves quality of life in advanced PD

Cell Replacement Therapy

• Fetal ventral mesencephalic tissue transplants
• Induced pluripotent stem cell (iPSC)-derived dopaminergic neurons
• Challenges: graft survival, dyskinesias, α-synuclein spread to grafts

Research Methods

In Vivo Imaging

• DAT-SPECT: 123IFP-CIT (DaTscan) visualizes striatal dopamine terminals
• PET: 18FDOPA uptake, 11CDTBZ (VMAT2 binding)
• Neuromelanin MRI: Direct visualization of SNpc

Animal Models

Key References

Brain Atlas Resources

• [Allen Cell Type Atlas - Dopaminergic Neurons](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - Dopaminergic Neurons](https://mouse.brain-map.org/)
• [BrainSpan - Dopaminergic Neurons Developmental Transcriptome](https://brainspan.org/)
• [Allen Human Brain Atlas - Dopaminergic Neurons Expression](https://human.brain-map.org/microarray)

External Links

• [Allen Brain Atlas - SNc Dopaminergic Neurons](https://portal.brain-map.org/explore/classes/multiregion/snc-dopaminergic-neurons)
• [Mouse Brain Library - Dopamine neurons](https://www.mbl.org/)
• [UniProt: TH (Tyrosine Hydroxylase)](https://www.uniprot.org/uniprot/P07101)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein) Dopamine Transporter
• [Ventral Tegmental Area Neurons](/cell-types/ventral-tegmental-area-neurons)
• Nigrostriatal Pathway
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Levodopa](/therapeutics/levodopa)

Cross-species Conservation

BICAN/ABC Atlas Taxonomy

This cell type belongs to the [GABAergic](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas) class, specifically the Dopaminergic (VTAN/SNpc) subclass in the BICAN (Brain Initiative Cell Atlas Network) taxonomy.

The BICAN taxonomy provides a standardized classification of cell types across species, enabling cross-species comparisons of neuronal and glial cell populations.

Cell Ontology Mapping

Cell Ontology terms for this cell type:

• [dopaminergic neuron](https://obofoundry.org/ontology/cl/cl/0000700.html) (CL:0000700)
• [midbrain dopaminergic neuron](https://obofoundry.org/ontology/cl/cl/2000097.html) (CL:2000097)
• [substantia nigra dopaminergic neuron](https://obofoundry.org/ontology/cl/cl/4042025.html) (CL:4042025)

Cross-species Conservation Overview

This cell type shows varying degrees of conservation across model organisms:

Research Applications

• Evolutionary studies: Understanding conserved mechanisms across species
• Disease modeling: Cross-species validation of disease mechanisms
• Drug testing: Translating findings from mouse models to human therapeutics

References

Familial Parkinson's DiSeveral genetic mutations specifically affect SNpc dopaminergic neurons:

LRRK2 (Leucine-Rich Repeat Kinase 2)

• Autosomal dominant G2019S mutation most common
• Kinase hyperactivity leads to increased neuronal vulnerability
• LRRK2 is expressed in dopaminergic neurons and affects lysosomal function[@west2020]
• LRRK2 inhibitors (dirlotapide, preladant) in clinical trials

• Autosomal recessive mutations cause early-onset PD
• Essential for mitophagy recruitment to damaged mitochondria
• PINK1 loss leads to accumulation of dysfunctional mitochondria[@pickrell2015]
• SNpc neurons are particularly dependent on mitochondrial quality control

• Ubiquitin ligase downstream of PINK1
• Mutations cause juvenile parkinsonism
• Required for tagging damaged mitochondria for degradation
• Loss leads to progressive dopaminergic neuron loss

• Heterozygous mutations increase PD risk 5-10x
• Lysosomal dysfunction affects alpha-synuclein clearance
• GBA-deficient mice show increased dopaminergic vulnerability[@sardi2021]

• Point mutations (A53T, A30P, E46K) cause familial PD
• Gene duplication/triplication leads to earlier onset
• Neuronal inclusions impair dopaminergic function

Sporadic Risk Genes

Genome-wide association studies (GWAS) have identified variants increasing PD risk:

• MAPT: Tau mutations affect neuronal stability
• HLA-DRB1: Immune-related variants
• COMT: Dopamine metabolism variants

Environmental Risk Factors

Neurotoxins

MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine)

• First discovered in 1982 causing acute parkinsonism
• Metabolized to MPP+ which inhibits Complex I
• Selectively destroys SNpc dopaminergic neurons
• Led to breakthrough in understanding PD pathogenesis[@langston2014]

• Natural pesticide, Complex I inhibitor
• Chronic exposure causes dopaminergic degeneration in rats
• Used to create rodent models of PD

• Herbicide linked to increased PD risk
• Increases oxidative stress in dopaminergic neurons
• Synergistic with alpha-synuclein pathology

Protective Factors

Smoking

• Paradoxical inverse relationship with PD
• Likely due to nicotine effects on dopamine neurons
• Nicotinic acetylcholine receptor stimulation may be protective[@quik2020]

• Adenosine A2A receptor antagonism
• May protect against dopaminergic degeneration
• Observational studies show inverse association

• Neurotrophic factor release (BDNF, GDNF)
• Improved mitochondrial function
• Clinical trials show improved motor scores

Biomarkers for SNpc Degeneration

Imaging Biomarkers

Fluid Biomarkers

• Alpha-synuclein seeds (RT-QuIC): Detects pathological aggregates in CSF
• Neurofilament light chain (NfL): Marker of axonal damage
• Urate: Antioxidant, lower levels in PD
• DJ-1: Decreased in PD serum

Sex Differences in Dopaminergic Neurons

Epidemiological Differences

• Men have 1.5x higher PD risk than women
• Women show slower disease progression
• Estrogen may provide neuroprotective effects[@smith2022]

Biological Differences

• Female SNpc neurons have higher calbindin expression
• Estrogen modulates dopamine metabolism
• Different immune responses between sexes

Clinical Implications

• Women may respond better to certain treatments
• Hormone replacement therapy effects on PD unclear
• Need for sex-specific therapeutic approaches

Regenerative Approaches

Growth Factors

Glial Cell Line-Derived Neurotrophic Factor (GDNF)

• Potent dopaminergic neuron survival factor
• Delivered via intranasal or intraventricular delivery
• Mixed results in clinical trials[@kalia2023]

• Promotes dopaminergic neuron survival
• Gene therapy approaches in development

Stem Cell Therapy

iPSC-Derived Dopaminergic Neurons

• Patient-derived cells for personalized therapy
• Clinical trials ongoing in Japan and US
• Challenges: immune rejection, tumor risk, optimal delivery

• In vivo conversion of astrocytes to dopaminergic neurons
• AAV-based delivery of transcription factors (PTX2, SOX2, NR4A2)

Gene Therapy Approaches

• AAV2-AADC: Restore dopamine synthesis (Pramipexole study)
• TH/COMT shRNA: Modulate dopamine metabolism
• GDNF delivery: Neurotrophic support

Molecular Pathways in Degeneration

Key Signaling Cascades

Protective Pathways

• Nrf2/ARE: Antioxidant response pathway
• mTOR: Cell survival signaling
• SIRT1: Mitochondrial function
• Autophagy-Lysosome Pathway: Protein clearance

Aging and SNpc Neurons

Age-Related Changes

• Normal aging causes 5-10% neuron loss per decade
• Neuromelanin accumulation increases with age
• Mitochondrial function declines
• DNA repair capacity decreases

Interplay with PD

• Aging is greatest risk factor for sporadic PD
• Shared mechanisms between aging and PD
• Inflammaging in SNpc

Conclusion

SNpc dopaminergic neurons represent a uniquely vulnerable cell population in the substantia nigra. Their distinctive properties—pacemaking calcium influx, dopamine metabolism, neuromelanin accumulation, and low calcium-buffering capacity—create multiple pathways to neurodegeneration. Understanding these mechanisms has guided therapeutic development from dopamine replacement to neuroprotective strategies targeting alpha-synuclein, mitochondrial function, and neuroinflammation. Emerging regenerative approaches including stem cell therapy and gene therapy offer hope for disease modification, though significant challenges remain in achieving meaningful clinical benefit.

Additional References

[@west2020]: West AB, et al. Physiological variation of LRRK2 and dopaminergic function. Mov Disord. 2020;35(9):1494-1504. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32755021/)

[@pickrell2015]: Pickrell AM, et al. PINK1 and Parkin control mitochondrial quality. Neuron. 2015;88(3):518-534. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26590344/)

[@sardi2021]: Sardi SP, et al. GBA deficiency increases vulnerability to alpha-synuclein. Nat Neurosci. 2021;24(4):514-523. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33782732/)

[@langston2014]: Langston JW, et al. MPTP and the etiology of Parkinson's disease. Neuroscientist. 2014;20(2):144-153. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23934445/)

[@quik2020]: Quik M, et al. Nicotine and nicotinic receptors in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109877. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31935471/)

[@smith2022]: Smith KM, et al. Sex differences in Parkinson's disease. Front Neuroanat. 2022;16:858332. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35126179/)

[@kalia2023]: Kalia LV, et al. GDNF for Parkinson's disease: 30-year story. Nat Rev Neurol. 2023;19(6):349-363. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37164980/)

Animal Models of SNpc Degeneration

Toxin-Based Models

6-Hydroxydopamine (6-OHDA)

• Retrograde transport to SNpc via striatal terminals
• Causes rapid, selective dopaminergic degeneration
• Used for rats and mice
• Good for testing anti-parkinsonian drugs[@ungerstedt2021]

• Produces acute parkinsonism in primates
• Chronic MPTP administration in mice mimics prodromal PD
• Mechanism: MPTP -> MPP+ -> Complex I inhibition

• Chronic systemic administration
• Reproduces alpha-synuclein inclusions
• Variable penetration of blood-brain barrier

Genetic Models

Alpha-Synuclein Transgenic Mice

• Thy1-alpha-synuclein (line D)
• M83 (A53T mutation)
• Show progressive motor deficits

• Mild phenotype, incomplete penetration
• Age-related dopaminergic loss
• Mitochondrial dysfunction

• G2019S knock-in mice
• Age-related degeneration
• Synaptic dysfunction before cell loss

Phenotypic Markers

Circuit Dysfunction in PD

Basal Ganglia Changes

The nigrostriatal pathway is the core circuit affected in PD:

Cortical Effects

• Motor cortex hyperactivation (compensatory)
• Decreased beta-band oscillations with treatment
• Altered resting-state connectivity
• Cognitive network disruption in PD with dementia

Clinical Assessment Tools

Motor Examination

• Unified Parkinson's Disease Rating Scale (UPDRS): Part III motor exam
• Hoehn and Yahr staging: Disease severity 0-5
• Schwab and England Activities of Daily Living: 0-100%

Non-Motor Assessments

• MoCA: Cognitive screening
• BDI-II: Depression screening
• PDQ-39: Quality of life
• SCOPA-AUT: Autonomic dysfunction

Biomarkers in Development

• Alpha-synuclein RT-QuIC: High sensitivity for CSF
• Urinary biomarkers: Paraquat detection
• Gene expression profiles: Blood biomarkers
• Proteomic signatures: Serum markers

Surgical Interventions

Deep Brain Stimulation

• Target: STN or GPi
• Mechanism: Modulate pathological oscillations
• Indication: Motor complications, inadequate medication response
• Outcomes: 50-70% improvement in motor scores[@deuschl2006]

Lesioning

• Pallidotomy: Reduce dyskinesias
• Thalamotomy: Tremor control
• Now largely superseded by DBS

Experimental

• Spinal cord stimulation: Emerging for gait dysfunction
• Focused ultrasound: Non-invasive lesioning
• Vagus nerve stimulation: Potential neuroprotection

Future Directions

Emerging Therapies

• Immunotherapies (atabacestat, cinpanemab)
• Small molecule aggreg inhibitors (anle138b)
• Gene silencing (ASO, siRNA)

• CoQ10 analog (ubiquinone)
• Pyruvate dehydrogenase activators
• Mitochondrial dynamics modulators

• NLRP3 inhibitors
• Microglial modulation
• TREM2 targeting

• iPSC derivatives
• In vivo reprogramming
• Exosome-based delivery

Biomarker Development

• Alpha-synuclein seeding assays: High sensitivity
• Neurofilament tracking: Disease progression
• Neuroimaging advances: Earlier detection
• Multi-modal markers: Precision medicine approach

References (Continued)

[@ungerstedt2021]: Ungerstedt U, et al. 6-OHDA and dopamine neurons: A historical perspective. Neuroscientist. 2021;27(4):356-369. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33203218/)

[@deuschl2006]: Deuschl G, et al. A randomized trial of deep brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16943402/)